Brensocatib: uses, dosing, side effects & brands
Brensocatib is a medicine sold in the U.S. under one brand, for bronchiectasis. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Bronchiectasis
- Available as
- Tablet
- Sold as
- Brinsupri
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How brensocatib is dosed
From the FDA label for Brinsupri (application NDA217673). Other brensocatib products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Recommended dosage: 10 mg or 25 mg orally once daily with or without food. ( 2.1 ) 2.1 Recommended Dosage The recommended dosage of BRINSUPRI is as follows: 10 mg orally once daily with or without food or 25 mg orally once daily with or without food Missed Dose(s) Patients who miss a dose should take the next dose at their regular time the next day. Do not double the dose to make up for the missed dose.
Brensocatib side effects
The following adverse reactions are described elsewhere in the labeling: Dermatologic Adverse Reactions [see Warnings and Precautions (5.1) ] Gingival and Periodontal Adverse Reactions [see Warnings and Precautions (5.2) ] Most common adverse reactions (incidence ≥2%): upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, hypertension. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Insmed Incorporated at 1-844-4-INSMED or FDA at 1-800-FDA-1088 or https://www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data below reflect the safety of BRINSUPRI in adult and pediatric patients aged 12 years and older with non-cystic fibrosis bronchiectasis (NCFB). A total of 1721 patients with NCFB were randomized in a double-blind, placebo-controlled clinical trial of 52 weeks duration (ASPEN) [see Clinical Studies (14) ]. The safety of BRINSUPRI was based on data from 1719 adult and pediatric patients aged 12 years and older who received at least one dose of BRINSUPRI or placebo. A total of 1156 patients received at least one dose of BRINSUPRI 10 mg or 25 mg orally once daily. Table 1…
Who shouldn’t take brensocatib
None. None. ( 4 )
Every brensocatib product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Brinsupri.
What brensocatib pills look like
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
What people report to the FDA about brensocatib
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 16 reports naming brensocatib, and the FDA flagged 50% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- balance disorder3 reports
- blood calcium abnormal2 reports
- blood creatinine increased2 reports
- blood potassium abnormal2 reports
- blood urea increased2 reports
- bradycardia2 reports
- dizziness2 reports
- electrocardiogram abnormal2 reports
Read these as a signal, not a rate. A report does not mean brensocatib caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is brensocatib?
BRINSUPRI (brensocatib) is a dipeptidyl peptidase 1 (DPP1) inhibitor.
Can you take brensocatib with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run brensocatib against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does brensocatib come in?
Across the brands we track, brensocatib is currently marketed as tablet, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic brensocatib?
We do not currently list a generic-labelled brensocatib product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Brensocatib: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/brensocatib
- MLA
- “Brensocatib: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/brensocatib.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for brensocatib on DailyMed (NIH) ↗.